Use of the proton pump inhibitor (PPI) pantoprazole does not cut the risk of upper gastrointestinal events but may reduce the risk of bleeding from gastroduodenal lesions in patients on low-dose anticoagulants and/or antiplatelet therapy, a study has shown.
Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.
Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, has shown potential in prevention of migraine at a range of doses, according to a presentation at the recent American Headache Society conference (AHS 2019).
A doctor in Singapore has recently been fined SGD 100,000 for failing to obtain informed consent from a patient prior to an injection of hydrocortisone and lignocaine (H&L). This disciplinary action has impacted the practice behaviour of some doctors in two aspects: avoidance behaviour and change in price for a service or procedure, according to a descriptive study.
Ketorolac, a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor, is effective and safe in preventing catheter-related bladder discomfort (CRBD) in men who have undergone robot-assisted laparoscopic radical prostatectomy (RALP), highlighting its potential role in postoperative CRBD management, a study shows.
Initiating therapy with a combination of immune modulators (IM) and antitumour necrosis factor (anti-TNF) agents appears to reduce the incidence of therapeutic ineffectiveness in patients with Crohn’s disease (CD) but not those with ulcerative colitis (UC), a recent study has found.
Treatment with onabotulinumtoxinA significantly improves headache-related outcomes in patients with chronic migraine (CM) regardless of their response status, according to a study presented at AHS 2019.
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.
Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau,
07 Aug 2019
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.